Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ocular Therapeutix Q2 EPS $(0.39) Misses $(0.36) Estimate, Sales $13.459M Beat $13.253M Estimate

Author: Benzinga Newsdesk | August 05, 2025 06:02am
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.03 percent. This is a 50 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $13.459 million which beat the analyst consensus estimate of $13.253 million by 1.56 percent. This is a 18.14 percent decrease over sales of $16.441 million the same period last year.

Posted In: OCUL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist